GlaxoSmithKline, SK Bioscience Start Final Trial Of COVID-19 Jab

The vaccine is facing a Phase 3 clinical trial to assess its "safety and immunogenicity" when compared with AstraZeneca's Covid vaccine.

British drugs giant GlaxoSmithKline and South Korean peer SK bioscience have begun final stage trials of a Covid-19 jab after positive early results, they announced Tuesday. The vaccine is facing a Phase 3 clinical trial to assess its "safety and immunogenicity" when compared with AstraZeneca's Covid vaccine, the two companies said in a joint statement. GSK is still trailing in the wake of Anglo-Swedish rival AstraZeneca, which rapidly developed a successful jab alongside Oxford University despite having little prior experience in vaccine development. The new jab combines SK bioscience's Covid vaccine candidate GBP510 with Glaxo's pandemic adjuvant that bolsters the immune response.